Blockade of the MR (mineralocorticoid receptor) in CKD (chronic kidney disease) reduces LVMI [LV (left ventricular) mass index] and proteinuria. The MR can be activated by aldosterone, cortisol and DOC (deoxycorticosterone). The aim of the present study was to explore the influence of mineralocorticoids on LVMI and proteinuria in patients with CKD. A total of 70 patients with CKD and 30 patients with EH (essential hypertension) were recruited. Patients underwent clinical phenotyping; biochemical assessment and 24 h urinary collection for THAldo (tetrahydroaldosterone), THDOC (tetrahydrodeoxycorticosterone), cortisol metabolites (measured using GC-MS), and urinary electrolytes and protein [QP (proteinuira quantification)]. LVMI was measured using CMRI (cardiac magnetic resonance imaging). Factors that correlated significantly with LVMI and proteinuria were entered into linear regression models. In patients with CKD, significant predictors of LVMI were male gender, SBP (systolic blood pressure), QP, and THAldo and THDOC excretion. Significant independent predictors on multivariate analysis were THDOC excretion, SBP and male gender. In EH, no association was seen between THAldo or THDOC and LVMI; plasma aldosterone concentration was the only significant independent predictor. Significant univariate determinants of proteinuria in patients with CKD were THAldo, THDOC, USod (urinary sodium) and SBP. Only THAldo excretion and SBP were significant multivariate determinants. Using CMRI to determine LVMI we have demonstrated that THDOC is a novel independent predictor of LVMI in patients with CKD, differing from patients with EH. Twenty-four hour THAldo excretion is an independent determinant of proteinuria in patients with CKD. These findings emphasize the importance of MR activation in the pathogenesis of the adverse clinical phenotype in CKD.
A B S T R A C T
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INTRODUCTION
Cardiovascular morbidity and mortality are markedly increased in patients with CKD (chronic kidney disease) compared with the general population [1, 2] . This increased risk is not fully explained by traditional cardiovascular risk factors [3] and at present conventional therapies aimed at addressing the risk are inadequate [4] . Excretion of urinary protein [5] , the presence of LVH (left ventricular hypertrophy) [6] and increased pulse wave velocity [7] are all independent predictors of mortality risk in CKD, with SBP (systolic blood pressure) being the best established determinant [8, 9] .
There remains, however, a need to explore further which additional factors contribute to end-organ damage in these patients. This will facilitate the development of therapies that target these pathogenic mechanisms and potentially reduce cardiovascular risk and preserve renal function.
In vivo studies have extensively demonstrated a causative role for mineralocorticoids in cardiac and renal damage in animals with renal impairment, particularly in the context of a high sodium environment [10, 11] . Most of these studies focus on the principal human mineralocorticoid, aldosterone, and the role of other less well-characterized mineralocorticoids [e.g. the aldosterone precursor DOC (deoxycorticosterone)], which also bind the MR (mineralocorticoid receptor), is unclear. In humans with hypertension, an elevated aldosterone level, particularly in relation to a suppressed plasma renin concentration, is associated with an elevated cardiovascular risk compared with patients with hypertension alone [12] . However, whether baseline levels of mineralocorticoids are associated with outcome in patients with CKD has not been studied.
Short-term small clinical trials have demonstrated a benefit in blocking the MR in CKD patients in terms of a reduction in proteinuria [13] , LV mass and pulse wave velocity [14] . However, the MR is activated by a number of ligands and so it may be that deleterious effects of MR activation are not all mediated by aldosterone. In this study, we aimed to explore the association between the excretion of urinary aldosterone and other, less well characterized, but physiologically relevant mineralocorticoid metabolites and LVMI (LV mass index), using gold-standard CMRI (cardiac magnetic resonance imaging) and proteinuria excretion in patients with CKD.
MATERIALS AND METHODS

Subject selection
Using a cross-sectional cohort design, 100 patients were consecutively recruited from local clinics. A total of 70 adult patients with CKD stages 2-4 were recruited from local renal clinics. Patients were included if they had DMN (diabetic nephropathy), IgAN (IgA nephropathy) or MGN (membranous nephropathy). The diagnosis of DMN was clinician defined in the majority of patients, i.e. patients with known diabetes mellitus (Type 1 or 2), microvascular complications, proteinuria and an absence of alternative explanation for their renal failure. The diagnosis of IgAN or MGN was made by native renal biopsy. A total of 30 patients with EH (essential hypertension) requiring drug treatment, and with normal kidney function, were recruited as control subjects from local hypertension clinics. Patients were matched for blood pressure control.
Patients were excluded if they had a condition that would interfere with aldosterone metabolism, such as a known aldosterone secreting tumour or adrenal hyperplasia, treatment with an aldosterone antagonist (spironolactone or eplerenone), or patients who were pregnant or lactating. Exclusion criteria for CMRI scanning were implantable ferromagnetic devices (n = 0), pacemaker (n = 1), obesity (weight >130 kg or waist circumference >120 cm) (n = 2) or claustrophobia (n = 10). Patients with active infection or receiving active immunosuppression were excluded. There was no upper threshold for proteinuria in renal patients.
Research was carried out in accordance with the Declaration of Helsinki (2008) of the World Medical Association. The protocol was approved by the local research ethics committee and all patients gave written informed consent.
Patient assessment
Patients took medication as prescribed. They attended the Glasgow Clinical Research Facility at 09.00 hours with a completed 24 h urine collection. From this, routine laboratory measurement of protein excretion, creatinine and electrolytes was carried out. Twentyfour hours excretion rates of urinary mineralocorticoid metabolites [THAldo (tetrahydroaldosterone), THDOC (tetrahydrodeoxycorticosterone), glucocorticoid metabolites, THF (tetrahydrocortisol), THE (tetrahydrocortisone) and allo-THE, and the cortisol precursor THS (tetrahydrodeoxycortisol)] were determined from 24 h urine aliquots by GC-MS using the Shackleton method [15] . After fasting overnight, patients underwent phenotyping including the lowest of three office blood pressure measurements, weight, height and waist circumference. After 30 min of supine rest venous blood was sampled for routine biochemistry and haematology. PRC (plasma renin concentration) was measured using the Diasorin analyser (Stillwater) (normal range undetectable, 40 m-units/l), and PAC (plasma aldosterone concentration) was measured using an RIA (TKAL2, Coat-A-Count; Siemens). Renal function was assessed using the six-variable MDRD (Modification of Diet in Renal Disease) formula. CMRI was performed using a 1.5 Tesla Siemens (Erlangan) scanner.
LVMI was calculated from short-axis cine imaging analysed using Argus software and adjusted for body surface area using the Mosteller formula as described previously [16] . Measurement of LVMI using this method was highly reproducible with 5.9 % interobserver variability. Utilizing published cut-offs, patients were determined to have LVH or not (males, LVMI >83.3 g/m 2 ; females, LVMI >66.8 g/m 2 ) [17] .
Data analysis
Data were analysed using SPSS version 15.0. Data were plotted to assess normality. Comparisons were made between groups using Student's t test or oneway ANOVA. Non-normally distributed data were compared using the Mann-Whitney U test or KruskallWallis test. Categorical data were compared using the χ 2 test. Correlations were Pearson's or Spearman's as appropriate. To take account of multiple comparisons, correlations at a significance level of P < 0.01 were deemed significant. Linear regression analysis was undertaken to assess the relationship between continuous variables.
RESULTS
Demographics
A total of 70 patients had CKD [34 DMN and 36 primary GN (glomerulonephritis)] and 30 patients had EH. Table 1 describes baseline clinical demographics. Patients with EH and CKD were well matched with no significant differences in gender, age, SBP, weight or LV mass. A total of 13 patients (12 CKD and one EH) were unable to undergo CMRI scanning. There were no significant differences between the demographics of these patients and those who were scanned.
Biochemical differences between the EH and CKD cohorts were as expected ( Table 2) . Renal patients had significantly lower eGFR (enhanced glomerular filtration rate) levels, and had higher concentrations of serum potassium and urate. Serum sodium was not significantly different between groups. Renal patients had higher levels of proteinuria and significantly lower urinary potassium excretion. PAC was not significantly different between EH and CKD groups or within CKD groups. Similarly, 24 h USod (urinary sodium) excretion did not differ. THAldo, THDOC, THS and total cortisol metabolite excretion did not differ between patient groups. Table 3 compares medication history between the two cohorts. CKD patients were significantly more likely to be prescribed an ACEi [ACE (angiotensinconverting enzyme) inhibitor], β-blocker or loop diuretic than patients with EH, who were more likely to be prescribed a thiazide diuretic. Excretion rates of THAldo Clearly, the possibility of interpreting these values is limited because patients were not prescribed individual drugs in isolation and the impact of different drugs on the RAAS (renin-angiotensin-aldosterone system) varies. Within the CKD cohort, patients with primary GN were significantly younger (54.8 compared with 61.8 years; P = 0.02) and had significantly lower SBP (138 compared with 157 mmHg; P < 0.001) than patients with DMN, who had poorer baseline renal function (eGFR, 32.4 compared with 47.6 ml/min per 1.73 m 2 ; P = 0.007) and higher LVMI (94.1 compared with 77.5 g/m 2 ; P = 0.002). There was no significant difference in urinary excretion rates of protein, steroids or sodium between groups. There was no significant difference in antihypertensive therapies between CKD groups.
Determinants of LVMI in CKD subjects
In patients with CKD, there was a significant correlation between LVMI and blood pressure [SBP (r = 0.55, P < 0.001), PP (pulse pressure) (r = 0.491, P < 0.001) and MAP (mean arterial pressure) (r = 0.459, P < 0.001)], urinary protein excretion [24 h QP (proteinuria quantification) (r = 0.538, P < 0.001) and uPCR (urine protein/creatinine ratio) (r = 0.513, P < 0.001)], and THAldo (r = 0.43, P = 0.001) and THDOC (r = 0.447, P = 0.001) excretion. LVMI was higher in male patients (P < 0.01). There was no significant correlation with between eGFR and LVMI or ACEi/ARB usage and LVMI. Significant correlates were entered individually into a univariate linear regression model, with the predicted variable of LVMI. Significant univariate predictors were then entered into a multivariate model. THAldo and THDOC excretion were entered separately into the models due to multicollinearity. Similarly, only the closest correlate measure of proteinuria (24 h QP) and measure of blood pressure (SBP) were entered into the model. Table 4 shows the multivariate model when THAldo was included, demonstrating that THAldo was a significant univariate predictor of LVMI in patients with CKD, but was not significant on multivariate analysis. Table 5 shows the multivariate model when THDOC was included and it can be seen that THDOC excretion, SBP and male gender were significant independent predictors of LVMI in patients with CKD on multivariate analysis. Quantified proteinuria was no longer a significant independent predictor of LVMI when THDOC or THAldo excretion were included in the model. The inclusion of eGFR in the model did not change the results and eGFR was not an independent predictor of LVMI. The regression analysis was not affected by adding primary renal diagnosis to the equation, suggesting the effect is uniform across both primary and secondary renal diagnoses (see Figure 2A) .
To ascertain whether there was a significant interaction between THDOC excretion, USod excretion and LVMI in patients with CKD, two-way ANOVA was carried out based on group tertiles which revealed no significant interaction, possibly due to small numbers in certain groups ( Figure 3A) . However, the subjects in the highest tertiles of both sodium and THDOC excretion had LVMI measurements that were several fold higher than those in the lowest tertiles of both ( Figure 3A ) although this did not reach statistical significance.
Determinants of LVMI in EH subjects
In patients with EH, there was a significant correlation between plasma aldosterone concentration (0.57, P = 0.001) and LVMI, which was not seen in CKD (Figure 1) . LVMI was similarly higher in males with EH (P < 0.01). Table 6 demonstrates that plasma aldosterone is the only significant independent predictor of LVMI in EH patients. Figure 2(B) demonstrates that urinary 
Determinants of proteinuria excretion in patients with CKD
Significant correlates (Spearman's correlation) with 24 h QP in patients with CKD were: SBP (r = 0.407, P = 0.001), pulse pressure (r = 0.318, P = 0.008), 24 h USod (r = 0.317, P = 0.009), THDOC excretion (r = 0.371, P = 0.002), THAldo (r = 0.426, P < 0.001) excretion and eGFR (r = − 0.271, P = 0.03). The positive correlates were entered into univariate linear regression models for prediction of log24 hQP and all were significantly predictive as seen in Table 7 . Two multivariate models were then constructed, entering THAldo and THDOC excretion separately with the other significant predictors. This showed that THAldo and SBP were the only significant independent predictors of proteinuria excretion.
Previous studies have suggested that aldosterone and sodium may interact synergistically to increase proteinuria excretion. Figure 3 (B) demonstrates graphically that patients in the highest tertile of urinary aldosterone excretion and highest tertile of USod excretion have the highest median 24 h proteinuria excretion, although this did not reach statistical significance. Patients with EH had very low or undetectable levels of proteinuria and were not analysed.
DISCUSSION
The results of the present study demonstrate novel associations between mineralocorticoid hormones and end-organ damage in patients with CKD. Specifically, DOC (as its major urinary metabolite THDOC) was an independent predictor of LVMI, while aldosterone (as THAldo) was an independent predictor of proteinuria. These findings provide insight into the pathogenesis of two significant predictors of cardiovascular morbidity and mortality in patients with CKD and further highlight the adverse effects of mineralocorticoids in this circumstance.
In addition, the present study highlights the disparity in the association of mineralocorticoids and end-organ damage between subjects with CKD and those with EH but normal renal function. The findings support the concept that excess cardiovascular risk seen in patients with CKD is not simply due to a clustering of traditional 
Figure 1 Relationship between log plasma aldosterone concentration and LVMI in patients with CKD (A) and EH (B)
The fitted linear regression line and estimate of significance are shown. NA, no association.
cardiovascular risk factors. The two groups were well matched in terms of baseline demographics, although serum potassium varied between groups, probably as a consequence of medication and underlying disease. DOC is produced in the zona fasciculata of the adrenal cortex and binds the MR with similar affinity to aldosterone, but is a weaker mineralocorticoid with a lower sodium retaining ability. There is, however, evidence that DOC can have marked potency in certain conditions. For example, the DOCA (DOC acetate)-salt rat is a well-established model of mineralocorticoid excess in humans. In this model, co-administration of DOCA and a high salt diet causes hypertension within 3 weeks [18] ; specifically, DOCA treatment causes a 30-fold increase in sodium absorption [19] . The initial receiving a high sodium diet resulted in LVH and increased perivascular collagen [20] . Rats treated with aldosterone similarly developed LVH but the distribution of collagen differed. These results have since been replicated by others who also demonstrated that these effects could be prevented or reversed by the addition of the MR antagonist, eplerenone [21, 22] . Finally, in humans, inherited deficiency of 11β-hydroxylase (in a rare form of congenital adrenal hyperplasia) results in elevated circulating DOC concentrations leading to mineralocorticoid hypertension in the majority of patients.
Taken together, these results clearly support a role for DOC in altering cardiac mass in the context of a high sodium environment via collagen deposition and myocyte hypertrophy, however, its potential role in influencing LV mass in humans has not been studied prior to this study. Our findings did identify a relationship between increasing THDOC, USod and LVMI in CKD although this did not reach statistical significance probably due to small numbers in some of the groups studied.
Ligand specificity of the MR in the renal distal tubule is maintained by 11BHSD2 (11β-hydroxysteroid dehydrogenase type 2), converting active cortisol (F) into inactive cortisone (E), leaving the MR free to bind to aldosterone. Recently, an analagous enzyme has been identified which protects the MR from DOC binding [23] . The aldo-keto reductase enzyme AKR1C3 (aldoketo reductase family 1 member C3) converts DOC into inactive 20α-hydroxy-DOC in renal cortical and medullary collecting ducts, preventing activation of the MR. If, in common with 11BHSD2, the AKR1C3 enzyme is not expressed in the heart, it may leave DOC free to bind the MR, explaining the independent effect of DOC on LV mass. This is an intriguing prospect that deserves further investigation.
Inhibition of the MR is the only pharmaceutical intervention demonstrated to regress LVH in patients with CKD. Edwards et al. [14] demonstrated that in 112 patients with non-diabetic CKD3, randomized to spironolactone 25 mg or placebo for 40 weeks in addition to ACE or ARB, spironolactone significantly reduced LV mass independent of reductions in SBP. Similar findings were observed in patients with EH in a separate study [24] . Indeed, as DOC is principally derived from the zona fasciculata of the adrenal cortex, and is regulated by ACTH (adrenocorticotrophin), use of ACEi or ARBs would not be expected to exert a significant effect on circulating levels. This may be one reason why these agents are less successful in resolving the raised LVMI in CKD, while MR blockade, which is ligand-independent, does. LVH is more common in patients with primary aldosteronism than in patients with EH [24] . Using echo, associations between PAC and LV mass have been reported in various subgroups, including patients with the metabolic syndrome [25] , overweight hypertensive black Americans [26] , hypertensive patients [27] or women only [28, 29] . Our finding in patients with EH that PAC was a significant independent predictor of LVMI supports the studies quoted above. Due to small numbers of females with EH in the study (n = 5), subgroup analysis was not performed.
There are, however, no studies assessing the relationship between aldosterone and LVMI in patients with CKD. Our findings that THAldo was a univariate predictor of LVMI but that THDOC was a significant independent predictor, suggest that mechanisms of increasing LV mass may differ between patients with CKD and patients with EH. Explanations for this are purely speculative but may relate to the modulating effects of uraemia, sodium and MR responsiveness. No correlation was seen between urinary mineralocorticoid excretion (THAldo and THDOC) and blood pressure [SBP and DBP (diastolic blood pressure)] in patients with CKD or EH. This would suggest that the association between levels of urinary mineralocorticoids and LVMI is due to a direct myocardial effect rather than indirectly by influencing afterload.
The finding that steroid excretion levels are similar in CKD and EH, patients is perhaps surprising and at odds with a previous study illustrating elevated plasma aldosterone levels in CKD. This may be due in part to the modulating effects of drug therapies. In addition, the data on which these assumptions are based involves patients with advanced renal failure (CrCl<10 ml/min) and is not relevant to the majority of patients with CKD [30] . Similarly, there is an assumption that secretion of aldosterone observes the expected diurnal variation in patients with CKD, which is largely ACTH-driven, but this has not been demonstrated experimentally. If this relationship was lost due to alterations in the hypothalamic-pituitary-adrenal axis in uraemia, it may explain the absence of an association between morning PAC and LVMI in patients with CKD, but the persistence of a relationship with 24 h urinary excretion. A further study by the Edwards group looked at corticosteroid excretion in their cohort of patients with mild, minimally proteinuric CKD and well-controlled blood pressure [31] . They found that PAC and THAldo were weakly correlated; that PAC (but not THAldo) was inversely correlated with eGFR; and that THAldo (but not PAC) correlated with DBP. These findings differ from our own. This may relate to differences in the study group; our patients had more advanced CKD, were heavier and we included patients with DMN. Furthermore, our patients had significantly higher levels of proteinuria and poorer blood pressure control despite a higher number of anti-hypertensives in our cohort. The competing influence of differing antihypertensive agents and baseline demographics may explain these differences.
We have demonstrated a positive relationship between sodium excretion, steroid excretion and both LVMI and proteinuria ( Figures 3A and 3B ). Both USod and urinary corticosteroid excretion are independent predictors of LVMI and proteinuria in CKD. The interaction between the two predictive factors did not, however, achieve statistical significance, probably due to small numbers in some of the combined groups. Nevertheless, the Figures illustrate a relationship consistent with the permissive effect of sodium on mineralocorticoid effects seen in experimental models [21, 22] . Thus the pattern in patients with CKD is comparable to the experimental findings in the uni-nephrectomized DOCA-salt rat. A larger study would be necessary to clarify the precise relationship between sodium and mineralocorticoids.
The degree of proteinuria excretion is an independent predictor of both progression of renal disease and mortality in patients with CKD. THAldo, THDOC and 24 h USod excretion were shown to be significant univariate predictors of proteinuria excretion in this cohort, with THAldo excretion and SBP being the only significant multivariate predictors. This has not been demonstrated before and concurs with experimental work detailing an association between the administration of aldosterone and proteinuria in rats, with associated glomerulosclerosis and interstitial fibrosis [10] . It also lends support to the concept that the reduction in proteinuria seen with blockade of the MR is due to mechanisms beyond reduction in blood pressure.
The study has limitations. This was a mixed 'real world' cohort and as such patients were prescribed multiple medications. As a cross-sectional analysis, the present study cannot assume causality and can only report associations. Using eGFR rather than direct measurement will introduce some inaccuracy, although the sixvariable MDRD formula is well-validated in patients with CKD. There are baseline differences between the different groups of renal diseases, reflecting their primary medical conditions; however, the baseline differences are unlikely to have influenced the study findings. Small patient numbers limit individual disease subgroup analysis, therefore, differences between diseases must be interpreted with caution as they may reflect underpowering of the study or differences between EH and CKD. It would also be interesting to expand the study to include patients with milder CKD as increases in LVMI have been seen in patients with preserved renal function and biopsy-proven GN [32] or APKD (autosomal-dominant polycystic kidney disease) [33] , but the relationship to steroid excretion is unclear. Including larger numbers of patients would also enhance understanding of whether there exists a relationship between steroids, sodium and LVMI.
Strengths of the present study include the use of 24 h urinary steroid excretion rates to provide an integrated measure of steroid status, free from the limitations of posture and diurnal variation which is acknowledged to provide a more accurate reflection of mineralocorticoid status albeit performed under controlled conditions. Similarly, the usage of CMRI to measure LV mass is superior to echocardiography or ECG measurement [34] and allows the use of smaller sample size due to the precision of the measurement.
Conclusions
Our observations provide additional support for the importance of mineralocorticoids in cardiorenal disease. They suggest that some other mineralocorticoid effect is mediated by DOC, and that DOC levels may be more strongly correlated with LVH than aldosterone. Furthermore, our data confirm the importance of sodium intake and demonstrate an important interaction between salt intake and mineralocorticoid effects.
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